BMS expands PeptiDream macrocyclic peptide alliance
This article was originally published in Scrip
Bristol-Myers Squibb has further extended its macrocyclic peptide drug discovery alliance with PeptiDream, providing further Big Pharma validation of the Japanese bioventure's technology and capabilities.
You may also be interested in...
Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.